Table 1.
The Characteristic Of The Included Studies
| Study | Intervention | Regimen In The CT Group | Follow-Up Time | Median Age (y) | Male (%) | Indication For Taking NOCA |
|---|---|---|---|---|---|---|
| ADVANCE 200924 | Apixaban | Enoxaparin | 12 days | 65.8 | 37.9 | VTE |
| ADVANCE-2 201023 | Apixaban | Enoxaparin | 12 days | 67 | 27.5 | VTE |
| ADVANCE-3 2010222 | Apixaban | Enoxaparin | 35 days | 60.8 | 46.7 | VTE |
| AMPLIFY 20134 | Apixaban | Warfarin | 6 months | 57 | 58.7 | VTE |
| AMPLIFY EXT 201325 | Apixaban | Placebo | 12 months | 56.7 | 57.4 | VTE |
| ARISTOTLE 201126 | Apixaban | Warfarin | 1.8 years | 70 | 64.7 | AF |
| AVERROES 201127 | Apixaban | Aspirin | 1.1 years | 70 | 58.5 | AF |
| RE-COVER 200934 | Dabigatran etexilate | Warfarin | 163 days | 54.7 | 58.4 | VTE |
| RE-COVER II 201443 | Dabigatran etexilate | Warfarin | 164 days | 54.9 | 60.6 | VTE |
| RE-MEDY 201340 | Dabigatran etexilate | Warfarin | 473 days | 54.7 | 60.9 | VTE |
| RE-SONATE 201340 | Dabigatran etexilate | Placebo | 164 days | 55.8 | 55.5 | VTE |
| RELY 200939 | Dabigatran etexilate | Warfarin | 2 years | 71.5 | 63.6 | AF |
| Chung, et al 201132 | Edoxaban | Warfarin | 3 months | 65.1 | 65.4 | AF |
| ENGAGE-AF-TIMI47 201328 | Edoxaban | Warfarin | 2.8years | 72 | 61.9 | AF |
| Fuji, et al 201431 | Edoxaban | Enoxaparin | 12 days | 76.1 | 20.5 | VTE |
| Hakusai-VTE 201333 | Edoxaban | Warfarin | 250 days | 55.8 | 57.2 | VTE |
| STARS E-3 201442 | Edoxaban | Enoxaparin | 13 days | 72.3 | 20.2 | VTE |
| STARS J-V 201544 | Edoxaban | Enoxaparin | 13 days | 62.8 | 14.1 | VTE |
| COMPASS 201730 | Rivaroxaban | Placebo | 23 months | 68.2 | 22 | CAD/PAD |
| EINSTEIN 201029 | Rivaroxaban | Placebo | 264 days | 56.1 | 56.8 | VTE |
| J-ROCKET AF 201238 | Rivaroxaban | Warfarin | 30 months | 71.1 | 80.6 | AF |
| RECORD1 200836 | Rivaroxaban | Enoxaparin | 35 days | 63.2 | 44.5 | VTE |
| RECORD2 200835 | Rivaroxaban | Enoxaparin | 35 days | 61.5 | 46.4 | VTE |
| RECORD4 200937 | Rivaroxaban | Enoxaparin | 12 days | 64.6 | 34.9 | VTE |
| ROCKET AF 201141 | Rivaroxaban | Warfarin | 590 days | 73 | 60.3 | AF |
Abbreviations: VTE, venous thromboembolism; AF, atrial fibrillation; CAD, coronary artery disease; PAD, peripheral artery disease; CT, conventional therapy.